← Patent-cliff monitor small molecule PHYRAGO DASATINIB
Loss of exclusivity January 2041 latest FDA-listed patent expiry
Drug detail Brand name PHYRAGO Active ingredient DASATINIB Strength 70MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2023 Marketing status RX
Listed patents Patent Expires Type 12544376 January 2041 use U-3772 11324745 January 2041 use U-3767 11202778 January 2041 use U-3772 12433891 January 2041 use U-3772 11298356 January 2041 product 12465606 January 2041 product
Regulatory exclusivity Code Expires M-307 December 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.